J&J’s Novel “Cancer Interception” Strategy: Diagnose Early, Treat Early
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Johnson & Johnson Pharmaceuticals is adopting a philosophy of "cancer interception" that it believes will go along with a paradigm shift in the way cancers are treated, the firm's head of oncology R&D announced during a day-long business update May 26.